AlphAIAlphAI — Financial news for AI agents
investing.comSEP 21 min read$GKOS

Glaukos chief development officer sells $2.48m in shares

Glaukos Corp's (GKOS) Chief Development Officer, Tomas Navratil, sold 13,744 shares worth $2.48m on August 28, 2026. Shares sold ranged from $179.69 to $182.50. GKOS stock is up 88% over the past year but has recently pulled back. Navratil now owns 73,890 shares. Glaukos reported Q2 2026 revenue of $185.6m, up 50% YoY, and raised its full-year sales outlook. Analysts have raised price targets, with Truist Securities setting a target of $215.

Original reporting
investing.com
Published Sep 2, 2026, 1:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 12:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBearishLow
01

Why it matters

The insider sale occurs after a positive earnings beat, creating mixed signals for investors.

02

Market read

While earnings were upbeat, the insider sale adds a modest bearish nuance.

03

What to watch

Recent strong earnings and raised guidance may offset concerns from the insider sale.

Relevance 5/10Novelty 6/10Timing: post‑sale, reported Sep 2 2026

Background

Glaukos reported strong Q2 results and raised its full‑year outlook, boosting analyst price targets.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Chief Development Officer sold $2.48M of GKOS shares on Aug 28, 2026, reducing his stake to 73,890 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is material for an insider but not large enough to trigger a major move; market may price in the reduced ownership.

Market effects

Sector

Limited; reflects a micro‑level change within the ophthalmic device sector.

Regional

None; the event is company‑specific.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine diversification rather than a negative signal.

Key entities

  • Executive
    Tomas Navratil

    Chief Development Officer of Glaukos Corp.

Read at source← All news

Related articles

AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 20
$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min